Purpose: To evaluate multiparametric magnetic resonance imaging/transrectal ultrasound (mpMRI/TRUS) fusion targeted biopsy (TB) of the prostate for prostate cancer (PCa) diagnosis. Patients and Methods: From April 2013 to January 2014, 53 men were included in this prospective single-centre study. The degree of PCa suspicion from mpMRI findings was classified according to the PI-RADS scoring system. Of these, 50 patients underwent both an mpMRI/TRUS fusion TB and a 10-core systematic biopsy (SB) of the prostate and were eligible for analysis. Results: 225 targeted and 500 systematic cores were included in this study. PCa was histologically confirmed in 52.0% of patients (26/50), whereas TB revealed PCa in 46.0% (23/50) and SB in 36.0% (18/50). TB identified PCa in 16.0% of all patients (8/50) that were missed by SB. All told, the targeted core was 2.8 times more likely to be PCa-positive than the systematic core (29.3 vs. 10.4%). Conclusions: mpMRI/TRUS fusion TB of the prostate is safe, practicable and may improve PCa diagnosis using fewer biopsy cores compared to SB.

Keywords:
Prostate imaging, Prostate fusion biopsy, Prostate cancer, Targeted biopsy
1.
Gómez Veiga F, Ponce Reixa J, Barbagelata López A, Fernández Rosado E, González Martín M: Current role of PSA and other markers in the diagnosis of prostate cancer. Arch Esp Urol 2006;59:1069-1082.
2.
Norberg M, Egevad L, Holmberg L, Sparén P, Norlén BJ, Busch C: The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 1997;50:562-566.
3.
Kurhanewicz J, Vigneron D, Carroll P, Coakley F: Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol 2008;18:71-77.
4.
Robertson NL, Emberton M, Moore CM: MRI-targeted prostate biopsy: a review of technique and results. Nat Rev Urol 2013;10:589-597.
5.
Schlemmer HP: Multiparametric MRI of the prostate: method for early detection of prostate cancer? Rofo 2010;182:1067-1075.
6.
Polanec SH, Helbich TH, Margreiter M, Klingler HC, Kubin K, Susani M, Pinker-Domenig K, Brader P: Magnetic resonance imaging-guided prostate biopsy: institutional analysis and systematic review. Rofo 2014;186:501-507.
7.
Puech P, Rouvière O, Renard-Penna R, Villers A, Devos P, Colombel M, Bitker MO, Leroy X, Mège-Lechevallier F, Comperat E, Ouzzane A, Lemaitre L: Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy - prospective multicenter study. Radiology 2013;268:461-469.
8.
Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Fütterer JJ; European Society of Urogenital Radiology: ESUR prostate MR guidelines 2012. Eur Radiol 2012;22:746-757.
9.
Junker D, Schäfer G, Kobel C, Kremser C, Bektic J, Jaschke W, Aigner F: Comparison of real-time elastography and multiparametric MRI for prostate cancer detection: a whole-mount step-section analysis. AJR Am J Roentgenol 2014;202:W263-W269.
10.
Wysock JS, Rosenkrantz AB, Huang WC, Stifelman MD, Lepor H, Deng FM, Melamed J, Taneja SS: A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: The PROFUS trial. Eur Urol 2014;66:343-351.
11.
Shigemura K, Motoyama S, Yamashita M: Do additional cores from MRI cancer-suspicious lesions to systematic 12-core transrectal prostate biopsy give better cancer detection? Urol Int 2012;88:145-149.
12.
Portalez D, Mozer P, Cornud F, Renard-Penna R, Misrai V, Thoulouzan M, Malavaud B: Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol 2012;62:986-996.
13.
Hoeks CM, Hambrock T, Yakar D, Hulsbergen-van de Kaa CA, Feuth T, Witjes JA, Fütterer JJ, Barentsz JO: Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging. Radiology 2013;266:207-217.
14.
Rastinehad AR, Turkbey B, Salami SS, Yaskiv O, George AK, Fakhoury M, Beecher K, Vira MA, Kavoussi LR, Siegel DN, Villani R, Ben-Levi E: Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy. J Urol 2014;191:1749-1754.
15.
Ashley RA, Inman BA, Routh JC, Mynderse LA, Gettman MT, Blute ML: Reassessing the diagnostic yield of saturation biopsy of the prostate. Eur Urol 2008;53:976-981.
16.
Pokorny MR, de Rooij M, Duncan E, Schröder FH, Parkinson R, Barentsz JO, Thompson LC: Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol 2014;66:22-29.
17.
Langer DL, van der Kwast TH, Evans AJ, Sun L, Yaffe MJ, Trachtenberg J, Haider MA: Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2 - sparse versus dense cancers. Radiology 2008;249:900-908.
18.
Rosenkrantz AB, Taneja SS: Radiologist, be aware: ten pitfalls that confound the interpretation of multiparametric prostate MRI. AJR Am J Roentgenol 2014;202:109-120.
19.
Kolb TM, Lichy J, Newhouse JH: Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology 2002;225:165-175.
20.
Vourganti S, Rastinehad A, Yerram NK, Nix J, Volkin D, Hoang A, Turkbey B, Gupta GN, Kruecker J, Linehan WM, Choyke PL, Wood BJ, Pinto PA: Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol 2012;188:2152-2157.
21.
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N: EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent - update 2013. Eur Urol 2014;65:124-137.
22.
Mozer P, Rouprêt M, Le Cossec C, Granger B, Comperat E, de Gorski A, Cussenot O, Renard-Penna R: First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography-guided biopsies for the diagnosis of localised prostate cancer. BJU Int 2014, Epub ahead of print.
23.
de Rooij M, Crienen S, Witjes JA, Barentsz JO, Rovers MM, Grutters JP: Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective. Eur Urol 2014;66:430-436.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.